Singapore markets closed
Straits Times Index
3,145.81 -5.75 (-0.18%) Nikkei
27,116.11 -195.19 (-0.71%) Hang Seng
17,740.05 -272.10 (-1.51%) FTSE 100
6,991.09 -6.18 (-0.09%) BTC-USD
19,577.46 -456.78 (-2.28%) CMC Crypto 200
446.39 -8.64 (-1.90%)
BioCryst Pharmaceuticals, Inc. (BCRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:11PM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 2.64B |
| Enterprise value | 2.38B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/sales (ttm) | 12.75 |
| Price/book (mrq) | 56.59 |
| Enterprise value/revenue | 11.67 |
| Enterprise value/EBITDA | -19.09 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.05 |
| 52-week change 3 | -1.80% |
| S&P500 52-week change 3 | -14.73% |
| 52-week high 3 | 19.99 |
| 52-week low 3 | 7.61 |
| 50-day moving average 3 | 13.47 |
| 200-day moving average 3 | 13.11 |
Share statistics
| Avg vol (3-month) 3 | 2.59M |
| Avg vol (10-day) 3 | 2.38M |
| Shares outstanding 5 | 185.94M |
| Implied shares outstanding 6 | N/A |
| Float 8 | 167.68M |
| % held by insiders 1 | 0.97% |
| % held by institutions 1 | 83.13% |
| Shares short (14 Sept 2022) 4 | 28.82M |
| Short ratio (14 Sept 2022) 4 | 13.33 |
| Short % of float (14 Sept 2022) 4 | 17.38% |
| Short % of shares outstanding (14 Sept 2022) 4 | 15.50% |
| Shares short (prior month 14 Aug 2022) 4 | 27.35M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Dec 2021 |
| Most-recent quarter (mrq) | 29 Jun 2022 |
Profitability
| Profit margin | -102.96% |
| Operating margin (ttm) | -89.11% |
Management effectiveness
| Return on assets (ttm) | -28.79% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 203.61M |
| Revenue per share (ttm) | 1.11 |
| Quarterly revenue growth (yoy) | 31.20% |
| Gross profit (ttm) | -58.9M |
| EBITDA | -180.39M |
| Net income avi to common (ttm) | -209.64M |
| Diluted EPS (ttm) | -1.07 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 417.48M |
| Total cash per share (mrq) | 2.24 |
| Total debt (mrq) | 630.51M |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 5.19 |
| Book value per share (mrq) | -1.15 |
Cash flow statement
| Operating cash flow (ttm) | -161.29M |
| Levered free cash flow (ttm) | -145.31M |
© 2022 Yahoo. All rights reserved.
